Myriad Genetics, Inc. (MYGN)Healthcare | Diagnostics & Research | Salt Lake City, United States | NasdaqGS
5.86 USD
+0.03
(0.515%)
⇧
(July 13, 2026, 4 p.m.
EDT)
After hours: 5.86 |
Hot Take ↕ | July 11, 2026, 3:56 a.m. EDT
The long-term investment case is severely compromised by a catastrophic multi-year decline; the stock has lost over 83% of its value since 2016, with the most recent annual return being a devastating -79%. While the company trades at a low price-to-sales ratio, this reflects a market consensus that the business is failing, compounded by negative revenue growth (-20%) and negative operating cash flow. The balance sheet shows deteriorating returns on equity and assets, confirming structural weakness rather than a temporary dislocation. In the short term, the outlook remains bearish despite a recent price bounce. The statistical forecasting model predicts a further 10% drop over the next 45 days, and options flow confirms this pessimism with heavy put buying. The recent price surge appears to be a volatile reaction to news rather than a reversal of the downtrend, as the stock still trades significantly below its 200-day average. With no dividend to provide income and a high beta amplifying downside risk, the security offers no compelling entry point for either value or momentum investors. |
| Model | MAE |
|---|---|
| AutoARIMA ✓ | 0.132013 |
| AutoTheta | 0.140057 |
| AutoETS | 0.140166 |
| MSTL | 0.141399 |
Forecast horizon: 45 days | Selected: AutoARIMA
| Forecast Reliability | |
|---|---|
| Score | 50% |
| H-stat | 0.61 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.261 |
| Excess Kurtosis | -0.19 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Last Dividend Date | 2009-06-30 |
| Debt to Equity Ratio | 32.845 |
| Revenue per Share | 7.452 |
| Market Cap | 553,466,496 |
| Forward P/E | 38.78 |
| Beta | 1.64 |
| Profit Margins | -41.29% |
| Website | https://www.myriad.com |
As of July 11, 2026, 3:56 a.m. EDT: Speculators are heavily positioned for downside protection, evidenced by significant open interest in out-of-the-money puts (strikes 3.0 and 4.0) relative to calls. Call activity is concentrated in the money or at-the-money, suggesting a defensive stance rather than aggressive bullish speculation. Implied volatility is elevated on the short-dated puts, indicating fear of further declines.
| Date | Dividend | Yield % |
|---|---|---|
| 2009-07-01 | 1.75 | 6.725596 |
| 2009-06-15 | 1.75 | 4.932356 |
| Attribute | Value |
|---|---|
| 52 Week Change | 0.116858244 |
| Address1 | 322 North 2200 West |
| All Time High | 69.0 |
| All Time Low | 1.4375 |
| Ask | 7.37 |
| Ask Size | 2 |
| Audit Risk | 7 |
| Average Analyst Rating | 3.0 - Hold |
| Average Daily Volume10 Day | 1,704,820 |
| Average Daily Volume3 Month | 1,645,965 |
| Average Volume | 1,645,965 |
| Average Volume10Days | 1,704,820 |
| Beta | 1.637 |
| Bid | 4.27 |
| Bid Size | 2 |
| Board Risk | 1 |
| Book Value | 3.574 |
| City | Salt Lake City |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Compensation Risk | 2 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 5.86 |
| Current Ratio | 2.669 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,782,777,600 |
| Day High | 6.015 |
| Day Low | 5.67 |
| Debt To Equity | 32.845 |
| Display Name | Myriad Genetics |
| Earnings Call Timestamp End | 1,778,013,000 |
| Earnings Call Timestamp Start | 1,778,013,000 |
| Earnings Timestamp | 1,778,011,200 |
| Earnings Timestamp End | 1,785,873,600 |
| Earnings Timestamp Start | 1,785,873,600 |
| Ebitda | -111,900,000 |
| Ebitda Margins | -0.2009 |
| Enterprise To Ebitda | -3.599 |
| Enterprise To Revenue | 0.723 |
| Enterprise Value | 402,766,496 |
| Eps Current Year | 0.04778 |
| Eps Forward | 0.15111 |
| Eps Trailing Twelve Months | -4.31 |
| Esg Populated | 0 |
| Exchange | NMS |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fax | 801 584 3640 |
| Fifty Day Average | 4.6314 |
| Fifty Day Average Change | 1.2286 |
| Fifty Day Average Change Percent | 0.26527616 |
| Fifty Two Week Change Percent | 11.685824 |
| Fifty Two Week High | 8.59 |
| Fifty Two Week High Change | -2.73 |
| Fifty Two Week High Change Percent | -0.3178114 |
| Fifty Two Week Low | 3.53 |
| Fifty Two Week Low Change | 2.3300002 |
| Fifty Two Week Low Change Percent | 0.6600567 |
| Fifty Two Week Range | 3.53 - 8.59 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 812,986,200,000 |
| Float Shares | 85,994,151 |
| Forward Eps | 0.15111 |
| Forward P E | 38.7797 |
| Free Cashflow | -46,062,500 |
| Full Exchange Name | NasdaqGS |
| Full Time Employees | 2,700 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,782,864,000 |
| Gross Margins | 0.68060994 |
| Gross Profits | 379,100,000 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.03759 |
| Held Percent Institutions | 0.96481 |
| Implied Shares Outstanding | 94,448,210 |
| Industry | Diagnostics & Research |
| Industry Disp | Diagnostics & Research |
| Industry Key | diagnostics-research |
| Ir Website | http://investor.myriad.com/ |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Dividend Date | 1,246,406,400 |
| Last Dividend Value | 1.75 |
| Last Fiscal Year End | 1,767,139,200 |
| Last Split Date | 1,238,025,600 |
| Last Split Factor | 2:1 |
| Long Business Summary | Myriad Genetics, Inc., a molecular diagnostics and precision medicine company, develops molecular tests. The company offers molecular diagnostic tests for oncology, women's health, and pharmacogenomics. It also provides MyRisk Hereditary Cancer test, a DNA sequencing test for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic test, a DNA sequencing test for metastatic breast, ovarian, metastatic pancreatic, and metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic test, a tumor test that determines homologous recombination deficiency status in patients with ovarian cancer. In addition, the company offers Prolaris Prostate Cancer Prognostic test, an RNA expression tumor analysis for assessing the aggressiveness of prostate cancer; EndoPredict Breast Cancer Prognostic test, an RNA expression test for assessing the aggressiveness of breast cancer; Precise Tumor Molecular Profile test, a genomic profiling test; Prequel Prenatal Screen, a non-invasive prenatal screening test conducted using maternal blood to screen for severe chromosomal disorders in a fetus; Foresight Carrier Screen, a prenatal test for future parents to assess their risk of passing on a recessive genetic condition to their offspring; SneakPeek Early Gender DNA test, a non-invasive blood test that predicts the gender of a fetus; FirstGene; and GeneSight Psychotropic Mental Health Medication test, a DNA genotyping test to aid psychotropic drug selection for depression, anxiety, attention-deficit/hyperactivity disorder, and other mental health conditions. It has a license collaboration with Illumina, Inc.; University of Texas M.D. Anderson Cancer Center; Mayo Foundation for Medical Education and Research; Children's Medical Center in Boston; Institut Curie and INSERM; and Eurobio Scientific SA. The company was founded in 1991 and is headquartered in Salt Lake City, Utah. |
| Long Name | Myriad Genetics, Inc. |
| Market | us_market |
| Market Cap | 553,466,496 |
| Market State | PREPRE |
| Max Age | 86,400 |
| Message Board Id | finmb_31822 |
| Most Recent Quarter | 1,609,372,800 |
| Net Income To Common | -230,000,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 550,633,064 |
| Number Of Analyst Opinions | 8 |
| Open | 5.82 |
| Operating Cashflow | -26,200,000 |
| Operating Margins | -0.2141 |
| Overall Risk | 3 |
| Payout Ratio | 0.0 |
| Peg Ratio | 1.24 |
| Phone | 801 584 3600 |
| Post Market Change | 0.0 |
| Post Market Change Percent | 0.0 |
| Post Market Price | 5.86 |
| Post Market Time | 1,783,981,118 |
| Previous Close | 5.83 |
| Price Eps Current Year | 122.64546 |
| Price Hint | 2 |
| Price To Book | 1.6396196 |
| Price To Sales Trailing12 Months | 0.99365616 |
| Profit Margins | -0.41292998 |
| Quick Ratio | 1.646 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | hold |
| Recommendation Mean | 3.0 |
| Region | US |
| Regular Market Change | 0.0300002 |
| Regular Market Change Percent | 0.514583 |
| Regular Market Day High | 6.015 |
| Regular Market Day Low | 5.67 |
| Regular Market Day Range | 5.67 - 6.015 |
| Regular Market Open | 5.82 |
| Regular Market Previous Close | 5.83 |
| Regular Market Price | 5.86 |
| Regular Market Time | 1,783,972,801 |
| Regular Market Volume | 811,472 |
| Return On Assets | -0.07645 |
| Return On Equity | -0.23513001 |
| Revenue Growth | -0.208 |
| Revenue Per Share | 7.452 |
| Sand P52 Week Change | 0.20847368 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 5 |
| Shares Outstanding | 94,448,210 |
| Shares Percent Shares Out | 0.0907 |
| Shares Short | 8,563,849 |
| Shares Short Previous Month Date | 1,780,012,800 |
| Shares Short Prior Month | 8,552,791 |
| Short Name | Myriad Genetics, Inc. |
| Short Percent Of Float | 0.093 |
| Short Ratio | 4.91 |
| Source Interval | 15 |
| State | UT |
| Symbol | MYGN |
| Target High Price | 10.0 |
| Target Low Price | 4.0 |
| Target Mean Price | 6.25 |
| Target Median Price | 5.75 |
| Total Cash | 150,700,000 |
| Total Cash Per Share | 1.596 |
| Total Debt | 0 |
| Total Revenue | 557,000,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -4.31 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 5.75165 |
| Two Hundred Day Average Change | 0.10835028 |
| Two Hundred Day Average Change Percent | 0.01883812 |
| Type Disp | Equity |
| Volume | 811,472 |
| Website | https://www.myriad.com |
| Zip | 84,116 |